Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Aegros logo — Australia's hyperimmune specialists and the nation's other f...

Aegros

Australia's hyperimmune specialists and the nation's other fractionator.

Founded 2017 Australia Australia 92 employees Biotechnology, Health and Wellness

General Information

Company Name Aegros
Founded Year 2017
Location Australia Australia +1
Employees 92
Industries Biotechnology, Health and Wellness
Social

Get notified when Aegros moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Aegros

Aegros is an Australian biotechnology startup that specializes in hyperimmune therapies and plasma fractionation. The company's mission focuses on providing access to life-saving plasma drugs as a fundamental human right, rather than a privilege. Aegros has developed the Haemafrac®, a unique electroseparation process for plasma, which aligns with their patient-centric approach to innovation. The startup operates a TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, where they manufacture a hyperimmune immunoglobulin product targeting Covid-19, derived from convalescent plasma. Notably, Aegros is in the final stages of preparing a dossier for the registration of this hyperimmune against Covid-19 on the Australian Register of Therapeutic Goods (ARTG). Concurrently, the company is also upgrading its existing hyperimmune facility in Macquarie Park, NSW, to increase its plasma processing capacity to 100,000 liters per year. Founded in 2017, Aegros operates in the Biotechnology and Health and Wellness industries, marking its significant progress and potential impact within the healthcare sector.

Taxonomy: Therapeutic plasma products, Hyperimmune immunoglobulin, Plasma fractionation, Life-saving drugs, Innovation in healthcare, Hyperimmune facility, Convalescent plasma, Medical technology, Biopharmaceuticals, Therapeutic plasma facilities

No funding data available for Aegros yet.

Get notified when Aegros raises funding

Aegros Alternatives & Competitors

Aegros vs
Prothya Biosolutions
Prothya Biosolutions Belgium

Prothya Biosolutions aims to be a center of excellence in protein therapies for leading pharmaceutic...

Private Equity
712 employees
Biopharma, Biotechnology
Compare Aegros vs Prothya Biosolutions
Aegros vs
Creative Testing Solutions
Creative Testing Solutions United States

Largest nonprofit blood and plasma donor testing laboratory organization in the world with over 100...

574 employees
Health Care
Aegros vs
Octapharma
Octapharma Switzerland

Our passion drives us to provide new health solutions advancing human life

2674 employees
Also compare with: Aegros vs Plasmapp Global Plasmapp Global

FAQ About Aegros

Australia's hyperimmune specialists and the nation's other fractionator.
Aegros was founded in 2017.
Aegros is headquartered in Australia.
Aegros operates in the following industries: Biotechnology, Health and Wellness.
Aegros has approximately 92 employees.
Top alternatives and competitors to Aegros include Prothya Biosolutions, Creative Testing Solutions, Octapharma, CAF-DCF, Canadian Plasma Resources. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aegros and Prothya Biosolutions are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Aegros and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes